IGCS 2022 Master Session: Ovarian Cancer

Description

Held on Septener 30, 2022 at the IGCS 2022 Annual Global Meeting in New York City, USA. This session is dedicated to innovations in ovarian cancer biology, surgery and treatment. Speakers in this session will cover the role of “biology” in clinical outcomes and potential for surgical decision making, timing and new approaches. With the growing interest in intraoperative treatments, a critical appraisal of HIPEC will be performed. The second part will discuss current and emerging systemic therapies in the first-line setting and how the ongoing trials may change clinical practice. Next, several “hot topics” in ovarian cancer will be presented, including the mechanisms of resistance to PARP inhibitors, front-line maintenance therapy as part of standard-of-care (SOC) for at least 50% of women with ovarian cancer and the new and very promising developmental therapies. To close this session dedicated to ovarian cancer, a debate on the role of surgery for relapsed disease from the US and European perspectives will be debated.

Master Session: Ovarian Cancer
Chair(s)	Andreas Du Bois (Germany) Thomas J. Herzog (USA) Amit Oza (Canada) Isabella L. Ray-Coquard (France) Anil K. Sood (USA)
DEBATE 1: SHARPENING THE SCALPEL WITH MOLECULAR BIOLOGY	Moderated by Andreas Du Bois
Debate 1: Pro	Anil K. Sood (USA)
Debate 1: Con	Florian Heitz (Germany)
PANEL 1: POTENTIAL IMPACT ON STANDARD OF CARE: REVIEW OF PENDING TRIALS	Moderated by Amit Oza
Potential impact on standard of care: Review of pending trials - Overview	Isabella L. Ray-Coquard (France)
Potential impact on standard of care: Review of pending trials - Analysis	Bradley J. Monk (USA)
PANEL 2: DEVELOPMENTAL THERAPEUTICS	Moderated by Isabelle Ray-Coquard (France)
Overcoming PARP resistance	Amit Oza (Canada)
Leveraging new pathways for ovarian cancer	Shannon N. Westin (USA)
PANEL 3: Current level of evidence supporting HIPEC in clinical care	Moderated by Anil Sood (USA)
HIPEC: A Critical Appraisal of Promises and Challenges	Kathleen N. Moore (USA)
Is it ready for primetime? Addressing the knowledge gaps in HIPEC data	Thomas J. Herzog (USA)
DEBATE 2: SECONDARY CYTOREDUCTION	Moderated by Thomas Herzog (USA)
Debate 2: Pro	Andreas Du Bois (Germany)
Debate 2: Con	Robert L. Coleman (USA)

Summary


Availability:	On-Demand


Cost:	FREE

Create Account

Recommended

Radical Hysterectomy - Surgical Film Festival

$0.00 - $50.00

Upper Abdominal Surgery for Ovarian Cancer - Surgical Film Festival

$0.00 - $50.00

Endometrial Cancer Tumor Board: Matching the right therapy to the right patient

FREE

Second-Line Treatment Options for Patients with Recurrent Cervical Cancer. Review of Current Treatment and Future Directions - Webinar

FREE

Multidisciplinary Approach to Treating Advanced Endometrial Cancer - Webinar

FREE

Radical Vulvectomy and Complex Plastic Reconstruction - Surgical Film Festival

$0.00 - $50.00

Obstacles and solutions for worldwide implementation of the Molecular Endometrial Carcinoma Classification - Webinar

FREE

Radical Hysterectomy - Surgical Film Festival - Webinar

$0.00 - $50.00

Treatment Options for Platinum Resistant Ovarian Cancer

FREE

Preinvasive Disease Program

Preinvasive Disease Program is an IGCS member benefit.

FREE

DEBATE 1: SHARPENING THE SCALPEL WITH MOLECULAR BIOLOGY

PANEL 1: POTENTIAL IMPACT ON STANDARD OF CARE: REVIEW OF PENDING TRIALS

PANEL 3: Current level of evidence supporting HIPEC in clinical care